Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome
Naoki Aikawa,1 Yasushi Kawasaki2 1School of Medicine, Keio University, Tokyo, 2Ono Pharmaceutical Co, Ltd, Osaka, Japan Abstract: Acute respiratory distress syndrome is a serious condition that can arise following direct or indirect lung injury. It is heterogeneous and has a high mortality rate. Sup...
Saved in:
Main Authors: | Aikawa N (Author), Kawasaki Y (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2014-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Usefulness of a selective neutrophil elastase inhibitor, sivelestat, in acute lung injury patients with sepsis
by: Miyoshi S, et al.
Published: (2013) -
Preclinical efficacy investigation of human neutrophil elastase inhibitor sivelestat in animal model of psoriasis
by: A. S. Zhukov, et al.
Published: (2022) -
Clinical evaluation of sivelestat for acute lung injury/acute respiratory distress syndrome following surgery for abdominal sepsis
by: Tsuboko Y, et al.
Published: (2012) -
Efficacy Analysis and Prognostic Impact of Sivelestat Sodium in Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome
by: Xiao Che, et al.
Published: (2024) -
Flavonoids as inhibitors of human neutrophil elastase
by: Katarzyna Jakimiuk, et al.
Published: (2021)